ABL Bio Inc.

298380 · XKRX · Biotechnology · South Korea

Debt To Equity RatioGross Profit MarginRange Position 1yReturn 1y

Market Capitalization10.78T KRW

Trailing P/E-168.77 KRW

52-Week Change80.79 KRW

ABL Bio Inc., a biotech research company, focuses on the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. The company offers ABL301, which is in the phase 1 clinical stage for the treatment of parkinson's disease; ABL503 and ABL111 that is in phase 1 clinical stage for the treatment of solid tumor; and ABL102 for the treatment of solid and blood tumor. It also provides ABL103 for the treatment solid cancers; ABL104 for the treatment of solid tumor; and ABL105, which is in phase 1 clinical stage for the treatment of solid tumor. ABL Bio Inc. was incorporated in 2016 and is based in Seoul, South Korea.

Industry

Biotechnology

Healthcare sector · South Korea

Stories

Structural patterns identified in ABL Bio Inc.

Screen for these patterns

Key Metrics

Market Capitalization

10.78TKRW

AboveNormalMar 18, 2026

Trailing P/E

-168.77KRW

ExtremeMar 18, 2026

Revenue (TTM)

79.35BKRW

NormalMar 18, 2026

Coordination

Placeholder CorpCoordination

Example HoldingsCoordination

Sample IncCoordination

Supply Chain

Vaccine Supply Chain

The vaccine supply chain is shaped by three structural constraints that most manufacturing industries never encounter: cold chain integrity requires unbroken refrigeration from manufacturing to injection — with some products requiring ultra-cold storage at -70°C, biological manufacturing variability means vaccines are grown in living systems where yields fluctuate batch to batch and cannot be precisely controlled, and regulatory lot release requires every batch to be independently tested and approved before distribution — a process that takes weeks and cannot be skipped or parallelized.